查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1886063

全球免疫蛋白診斷檢測市場

Immunoprotein Diagnostic Testing
出版日期: | 出版商: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 英文 171 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

預計到2030年，全球免疫蛋白診斷檢測市場規模將達226億美元。

全球免疫蛋白診斷測試市場規模在2024年估計為167億美元，預計到2030年將達到226億美元，在分析期（2024-2030年）內複合年成長率（CAGR）為5.2%。本報告分析的細分市場之一—免疫球蛋白診斷測試，預計將以6.0%的複合年成長率成長，並在分析期結束時達到64億美元。遊離輕鏈診斷測試細分市場預計在分析期間內將以4.2%的複合年成長率成長。

美國市場規模估計為46億美元，而中國市場預計將以4.8%的複合年成長率成長。

預計到2024年，美國免疫蛋白診斷檢測市場規模將達46億美元。作為世界第二大經濟體，中國預計到2030年市場規模將達到35億美元，2024年至2030年的複合年成長率（CAGR）為4.8%。其他值得關注的區域市場分析包括日本和加拿大，預計在分析期間內，這兩個國家的複合年成長率將分別達到5.0%和4.2%。在歐洲，德國的複合年成長率預計將達到約4.3%。

全球免疫蛋白診斷檢測市場—主要市場趨勢與促進因素概述

為什麼免疫蛋白診斷檢測正逐漸成為疾病診斷與管理的重要工具

免疫蛋白診斷檢測已成為早期發現、診斷和後續觀察多種疾病和健康狀況（包括自體免疫疾病、感染疾病、心血管疾病和癌症）的重要工具。這些檢測旨在測量血液、血清或血漿樣本中特定免疫蛋白的水平，例如免疫球蛋白（IgA、IgG、IgM）、C反應蛋白（CRP）、補體蛋白和類風濕因子。透過檢測這些蛋白的異常濃度，免疫蛋白診斷檢測能夠提供有關發炎反應、免疫系統活性和疾病狀態的重要資訊。慢性病和自體免疫疾病的日益增多，以及對準確可靠的診斷工具的需求不斷成長，正推動著全球臨床檢查室、醫院和研究機構對免疫蛋白檢測的廣泛應用。

此外，檢查室自動化技術的進步、就地檢驗（POC​​T）需求的成長以及預防醫學意識的提高等因素，進一步推動了全球免疫蛋白診斷檢測市場的發展。自動化免疫檢測設備和多重檢測平台等技術創新，實現了更快、更準確、更經濟高效的診斷流程，進而提高了臨床檢查室的效率和生產力。此外，人們對預防醫學和疾病早期檢測的日益關注，也推動了對免疫蛋白診斷檢測的需求，這些檢測能夠提供有價值的資訊，幫助醫療專業人員及時採取干涉措施。免疫蛋白診斷在腫瘤學、感染疾病控制和個人化醫療等領域的廣泛應用，使該市場成為現代醫療保健的關鍵組成部分，有助於改善患者預後，並為臨床決策提供更充分的資訊。

哪些技術進步將改變免疫蛋白診斷檢測市場？

技術創新正在革新免疫蛋白診斷檢測市場，顯著提升檢測流程的準確性、速度與便利性。其中最具影響力的創新之一是高靈敏度和高特異性免疫檢測的開發，例如化學冷光酵素免疫分析法免疫檢測(ELISA)、化學發光免疫檢測(CLIA) 和放射免疫分析 (RIA)。這些先進的檢測技術能夠檢測到極微量的免疫蛋白，在臨床症狀出現之前即可對疾病進行早期診斷。能夠同時進行多項檢測的自動化免疫檢測設備的引入，簡化了臨床檢查室的工作流程，縮短了檢測結果的返回時間，並最大限度地減少了人為誤差。這些系統還具備高通量檢測能力，使其成為大規模篩檢計畫和醫院環境的理想選擇。

另一項變革性的技術進步是就地檢驗（POC​​T）設備的興起，它能夠在患者床邊、門診甚至家中快速進行免疫蛋白質診斷。 POCT設備設計易於使用、便於攜帶，並可在數分鐘內提供準確結果，從而加快臨床決策速度，並減少對中心檢查室檢測的需求。 POCT中橫向流動化驗、生物感測器和微流體裝置的應用，正在擴大免疫蛋白質診斷的覆蓋範圍，尤其是在傳統檢測設施有限的農村和醫療資源匱乏地區。此外，數位健康技術的整合，例如連接和數據共用功能，使得免疫蛋白質水平的即時監測和分析成為可能，從而支持遠端醫療和遠端患者管理。

其他創新包括應用多重檢測平台和生物晶片技術，這些技術能夠同時檢測單一檢體中的多種免疫蛋白質。這些技術能夠提供患者免疫反應的詳細圖譜，從而更全面地了解疾病狀態。人工智慧 (AI) 和機器學習 (ML) 演算法的整合也增強了對複雜免疫蛋白數據的解讀，能夠更準確地識別模式並預測疾病風險。 AI 驅動的診斷平台能夠分析大規模資料集，並為臨床醫生提供可操作的見解，從而幫助個人化和精準醫療轉型。這些技術進步正在革新免疫蛋白診斷檢測領域，使更快、更可靠、更全面的診斷解決方案成為可能，以滿足現代醫療保健不斷變化的需求。

市場動態與監管標準如何影響免疫蛋白診斷檢測市場？

免疫蛋白診斷檢測市場受複雜的市場動態和監管標準的影響，這些因素影響著產品的開發、應用和可及性。推動市場發展的關鍵因素之一是慢性病、自體免疫疾病和感染疾病的日益流行，這促使人們對能夠早期、準確檢測疾病的診斷工具的需求不斷成長。隨著類風濕性關節炎、全身性紅斑性狼瘡和多發性硬化症等疾病的全球負擔持續加重，迫切需要能夠評估免疫功能、監測疾病活動和評估治療反應的免疫蛋白診斷檢測。在腫瘤學領域，免疫蛋白標記被用於檢測和後續觀察某些類型的癌症，例如前列腺癌（使用前列腺特異性抗原：PSA）和多發性骨髓瘤（使用BETA2-微球蛋白），從而為治療決策和預後評估提供寶貴資訊。

監管標準和合規要求在塑造免疫蛋白診斷檢測市場方面也發揮關鍵作用。美國食品藥物管理局(FDA) 和歐洲藥品管理局 (EMA) 等監管機構制定了嚴格的診斷檢測開發、核准和商業化指南，以確保其安全性、有效性和可靠性。遵守這些法規對於製造商成功進入市場並維持醫療服務提供者和患者的信任至關重要。監管環境正在不斷發展，以跟上診斷技術的進步，尤其是在就地檢驗和數位健康解決方案方面。例如，FDA 的緊急使用授權 (EUA) 流程在 COVID-19 大流行期間被廣泛用於促進診斷檢測的快速供應，這凸顯了建立一個靈活敏捷的法規結構的必要性，該框架既能支持創新，又能確保患者安全。隨著新的診斷技術和平台的出現，監管機構正在完善政策，以解決資料隱私、網路安全和臨床檢驗等問題，這些問題對於確保免疫蛋白診斷檢測的品質和完整性至關重要。

市場動態，例如製造商之間的競爭、價格壓力和醫療報銷政策，也會影響免疫蛋白診斷檢測市場。競爭格局的特點是既有老牌企業，也有新參與企業，它們都在努力開發創新的診斷解決方案，並在這個快速發展的市場中站穩腳跟。各公司透過產品創新、策略聯盟以及提供涵蓋檢測設備、軟體、數據分析和支援服務的綜合診斷解決方案來脫穎而出。價格壓力，尤其是在成本敏感市場，正在推動對兼具高性能和高品質且價格合理的診斷測試的需求。此外，醫療報銷政策和支付方的核保決策也在影響免疫蛋白診斷檢測的普及。不同地區的報銷環境差異顯著，並受多種因素影響，例如檢測的臨床效用、替代診斷方案的可用性以及整體醫療預算。對於在免疫蛋白診斷檢測市場中運作的公司而言，充分了解市場動態和監管標準至關重要，這將有助於它們擴大市場佔有率，並滿足患者和醫療服務提供者未被滿足的診斷需求。

推動免疫蛋白診斷檢測市場擴張的關鍵成長要素有哪些？

全球免疫蛋白診斷檢測市場的成長受多種關鍵因素驅動，包括慢性病和自體免疫疾病發生率的上升、對疾病早期檢測和預防保健的日益重視，以及診斷技術的進步。其中一個關鍵成長要素是慢性病和自體免疫疾病盛行率的不斷攀升，這導致對能夠早期準確檢測疾病的診斷測試的需求顯著增加。特別是自體免疫疾病，由於其症狀複雜且相互重疊，往往難以診斷。免疫蛋白診斷測試提供了一種可靠的方法來檢測自體免疫標記並評估疾病活動度，從而實現早期診斷和更有效的疾病管理。隨著全球人口老化加劇和這些疾病發病率持續上升，預計對免疫蛋白診斷測試的需求將會增加，從而推動市場擴張。

另一個關鍵成長要素是人們對疾病早期檢測和預防保健日益成長的興趣。早期發現心血管疾病、糖尿病和癌症等疾病可以顯著改善治療效果並降低醫療成本。免疫蛋白診斷測試能夠檢測發炎、感染疾病和惡性腫瘤的早期生物標記物，目前正被用於篩檢風險因子和監測疾病進展。對預防保健的日益重視促使醫療服務提供者和患者都採用能夠在健康問題出現臨床症狀之前識別它們的診斷測試。這一趨勢在北美和歐洲等已開發地區尤其明顯，這些地區的醫療保健系統越來越重視預防保健和健康促進措施。此外，個人化醫療的興起正在推動免疫蛋白診斷技術的應用，以根據個別患者的情況制定治療策略，從而進一步促進市場成長。

診斷檢測技術的進步也推動了免疫蛋白診斷檢測市場的成長。高通量免疫檢測平台、就地檢驗設備和數位健康解決方案等創新技術，使診斷檢測更加便利、準確且易用。能夠從單一檢體中檢測多種生物標記的多重檢測平台，提供了更全面的疾病狀態資訊，從而實現更精準的診斷和監測。連接性和數據共用等數位技術的應用，促進了免疫蛋白診斷融入更廣泛的醫療保健生態系統，支援遠端醫療和遠距患者管理。隨著技術創新不斷提升免疫蛋白診斷檢測的效能和可及性，對早期檢測和個人化醫療的日益重視，預計將推動全球免疫蛋白診斷檢測市場持續成長，而這主要得益於醫療服務提供者和患者對更有效診斷解決方案的需求不斷成長。

部分：

按類型（免疫球蛋白診斷、遊離輕鏈診斷、前白蛋白診斷、結合結合球蛋白蛋白診斷、C反應蛋白診斷、補體系統蛋白診斷、其他類型）；按技術（酵素免疫分析法、免疫比濁法、放射免疫測定、免疫蛋白免疫檢測、其他技術）；依應用（傳染病檢查、腫瘤檢測、自體免疫免疫檢測、內分泌檢測、過敏檢測、其他技術檢測、過敏檢測、其他技術檢測）

受訪公司範例

  • Abbott Laboratories
  • Abcam PLC
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation
  • DiaSorin SpA
  • Enzo Biochem, Inc.
  • F. Hoffmann-La Roche AG
  • Ortho Clinical Diagnostics
  • Siemens AG
  • Thermo Fisher Scientific, Inc.

人工智慧整合

我們正在利用檢驗的專家內容和人工智慧工具，革新市場和競爭情報分析。

Market Glass, Inc. 並沒有採用查詢LLM 或產業專用的SLM 的典型方法，而是建立了一個由世界各地領域專家精心策劃的內容庫，其中包括影片轉錄、BLOG、搜尋引擎研究以及大量的公司、產品/服務和市場數據。

關稅影響係數

在最新發布的報告中，Market Glass, Inc. 將關稅對地理市場的影響納入考量，並根據公司總部所在地、製造地以及進出口（成品和OEM產品）情況，預測企業競爭地位的變化。這種複雜多變的市場現實會從多個方面影響競爭對手，包括增加銷貨成本、降低盈利和重組供應鏈，同時也會影響微觀和宏觀市場動態。

目錄

第1章調查方法

第2章執行摘要

  • 市場概覽
  • 主要企業
  • 市場趨勢和促進因素
  • 全球市場展望

第3章 市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 其他歐洲
  • 亞太地區
  • 世界其他地區

第4章 競賽

簡介目錄
Product Code: MCP12539

Global Immunoprotein Diagnostic Testing Market to Reach US$22.6 Billion by 2030

The global market for Immunoprotein Diagnostic Testing estimated at US$16.7 Billion in the year 2024, is expected to reach US$22.6 Billion by 2030, growing at a CAGR of 5.2% over the analysis period 2024-2030. Immunoglobulin Diagnostic Testing, one of the segments analyzed in the report, is expected to record a 6.0% CAGR and reach US$6.4 Billion by the end of the analysis period. Growth in the Free Light Chain Diagnostic Testing segment is estimated at 4.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$4.6 Billion While China is Forecast to Grow at 4.8% CAGR

The Immunoprotein Diagnostic Testing market in the U.S. is estimated at US$4.6 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$3.5 Billion by the year 2030 trailing a CAGR of 4.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.0% and 4.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.3% CAGR.

Global Immunoprotein Diagnostic Testing Market - Key Trends & Drivers Summarized

Why is Immunoprotein Diagnostic Testing Emerging as a Vital Tool in Disease Diagnosis and Management?

Immunoprotein diagnostic testing has become an indispensable tool in the early detection, diagnosis, and monitoring of various diseases and health conditions, including autoimmune disorders, infectious diseases, cardiovascular diseases, and cancer. These tests are designed to measure the levels of specific immunoproteins-such as immunoglobulins (IgA, IgG, IgM), C-reactive protein (CRP), complement proteins, and rheumatoid factors-in blood, serum, or plasma samples. By detecting abnormal concentrations of these proteins, immunoprotein diagnostic tests provide crucial insights into the presence and progression of inflammatory responses, immune system activity, and disease states. The increasing prevalence of chronic and autoimmune diseases, along with the growing need for precise and reliable diagnostic tools, is driving the adoption of immunoprotein testing across clinical laboratories, hospitals, and research institutions worldwide.

The global immunoprotein diagnostic testing market is further fueled by advancements in laboratory automation, the rising demand for point-of-care testing (POCT), and the growing awareness of preventive healthcare. Technological innovations such as automated immunoassay analyzers and multiplex testing platforms are enabling faster, more accurate, and cost-effective diagnostic processes, enhancing the efficiency and productivity of clinical laboratories. Moreover, the increasing focus on preventive healthcare and early disease detection is boosting the demand for immunoprotein diagnostic tests as they provide valuable information that helps healthcare providers initiate timely interventions. The expanding applications of immunoprotein diagnostics in oncology, infectious disease management, and personalized medicine are positioning this market as a critical component of modern healthcare, supporting better patient outcomes and more informed clinical decision-making.

What Technological Advancements Are Transforming the Immunoprotein Diagnostic Testing Market?

Technological advancements are significantly transforming the immunoprotein diagnostic testing market by enhancing the accuracy, speed, and convenience of testing procedures. One of the most impactful innovations is the development of high-sensitivity and high-specificity immunoassays, such as enzyme-linked immunosorbent assays (ELISA), chemiluminescence immunoassays (CLIA), and radioimmunoassays (RIA). These advanced assay technologies enable the detection of even minute concentrations of immunoproteins, making it possible to diagnose diseases at very early stages when clinical symptoms may not yet be apparent. The introduction of automated immunoassay analyzers that can perform multiple tests simultaneously is streamlining workflow in clinical laboratories, reducing turnaround times, and minimizing the potential for human error. These systems are also capable of handling high-throughput testing, making them ideal for large-scale screening programs and hospital settings.

Another transformative technological advancement is the rise of point-of-care testing (POCT) devices that allow for rapid immunoprotein diagnostics at the patient’s bedside, in outpatient settings, or even at home. POCT devices are designed to be user-friendly, portable, and capable of delivering accurate results within minutes, facilitating faster clinical decisions and reducing the need for centralized laboratory testing. The use of lateral flow assays, biosensors, and microfluidic devices in POCT is expanding the accessibility of immunoprotein diagnostics to a wider population, particularly in rural and underserved areas where access to traditional laboratory facilities may be limited. Additionally, the integration of digital health technologies, such as connectivity features and data-sharing capabilities, is enabling real-time monitoring and analysis of immunoprotein levels, supporting telemedicine and remote patient management.

Further innovations include the application of multiplex testing platforms and biochip technologies, which allow for the simultaneous measurement of multiple immunoproteins from a single sample. These technologies are providing a more comprehensive understanding of disease states by offering a detailed profile of the patient’s immune response. The integration of artificial intelligence (AI) and machine learning (ML) algorithms is also enhancing the interpretation of complex immunoprotein data, identifying patterns, and predicting disease risk with greater accuracy. AI-driven diagnostic platforms can analyze large datasets and provide clinicians with actionable insights, supporting the shift towards personalized and precision medicine. These technological advancements are revolutionizing the field of immunoprotein diagnostic testing, making it possible to deliver faster, more reliable, and more comprehensive diagnostic solutions that cater to the evolving needs of modern healthcare.

How Are Market Dynamics and Regulatory Standards Influencing the Immunoprotein Diagnostic Testing Market?

The immunoprotein diagnostic testing market is shaped by a complex set of market dynamics and regulatory standards that are influencing product development, adoption, and accessibility. One of the primary market drivers is the increasing prevalence of chronic diseases, autoimmune disorders, and infections, which is creating a growing demand for diagnostic tools that can provide early and accurate disease detection. As the global burden of diseases such as rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis continues to rise, there is a heightened need for immunoprotein diagnostic tests that can assess immune function, monitor disease activity, and evaluate treatment efficacy. In oncology, immunoprotein markers are being used to detect and monitor certain types of cancers, such as prostate cancer (using prostate-specific antigen, or PSA) and multiple myeloma (using beta-2 microglobulin), providing valuable information for guiding treatment decisions and assessing prognosis.

Regulatory standards and compliance requirements are also playing a critical role in shaping the immunoprotein diagnostic testing market. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have established stringent guidelines for the development, approval, and commercialization of diagnostic tests to ensure their safety, efficacy, and reliability. Compliance with these regulations is essential for manufacturers to gain market access and maintain the trust of healthcare providers and patients. The regulatory landscape is evolving to keep pace with advances in diagnostic technologies, particularly with regard to point-of-care testing and digital health solutions. For instance, the FDA’s Emergency Use Authorization (EUA) process, which was widely used during the COVID-19 pandemic to expedite the availability of diagnostic tests, has highlighted the need for flexible and responsive regulatory frameworks that can support innovation while ensuring patient safety. As new diagnostic technologies and platforms emerge, regulatory agencies are refining their policies to address issues such as data privacy, cybersecurity, and clinical validation, which are critical for ensuring the quality and integrity of immunoprotein diagnostic tests.

Market dynamics such as competition among manufacturers, pricing pressures, and healthcare reimbursement policies are also influencing the immunoprotein diagnostic testing market. The competitive landscape is characterized by the presence of both established players and new entrants, each striving to develop novel diagnostic solutions and gain a foothold in this rapidly evolving market. Companies are differentiating themselves through product innovation, strategic partnerships, and the ability to offer comprehensive diagnostic solutions that include not only testing devices but also software, data analytics, and support services. Pricing pressures, particularly in cost-sensitive markets, are driving the demand for cost-effective diagnostic tests that offer high performance without compromising quality. Additionally, healthcare reimbursement policies and coverage decisions by payers are impacting the adoption of immunoprotein diagnostic tests. The reimbursement environment varies significantly across regions and is influenced by factors such as the clinical utility of the test, the availability of alternative diagnostic options, and the overall healthcare budget. Navigating these market dynamics and regulatory standards is essential for companies operating in the immunoprotein diagnostic testing market as they seek to expand their presence and address the unmet diagnostic needs of patients and healthcare providers.

What Are the Key Growth Drivers Fueling the Expansion of the Immunoprotein Diagnostic Testing Market?

The growth in the global immunoprotein diagnostic testing market is driven by several key factors, including the rising incidence of chronic and autoimmune diseases, increasing focus on early disease detection and preventive healthcare, and advancements in diagnostic technologies. One of the primary growth drivers is the growing prevalence of chronic and autoimmune diseases, which is creating a significant demand for diagnostic tests that can provide early and accurate detection. Autoimmune diseases, in particular, are often difficult to diagnose due to their complex and overlapping symptoms. Immunoprotein diagnostic tests offer a reliable means of detecting autoimmune markers and assessing disease activity, enabling earlier diagnosis and more effective disease management. As the global population ages and the incidence of these conditions continues to rise, the demand for immunoprotein diagnostics is expected to increase, supporting market expansion.

Another significant growth driver is the increasing focus on early disease detection and preventive healthcare. Early detection of diseases such as cardiovascular disease, diabetes, and cancer can significantly improve treatment outcomes and reduce healthcare costs. Immunoprotein diagnostic tests, which can detect early biomarkers of inflammation, infection, and malignancy, are being used to screen for risk factors and monitor disease progression. The growing emphasis on preventive healthcare is encouraging healthcare providers and patients to adopt diagnostic tests that can identify health issues before they become clinically apparent. This trend is particularly strong in developed regions such as North America and Europe, where healthcare systems are increasingly prioritizing preventive care and wellness initiatives. Additionally, the rise of personalized medicine is driving the use of immunoprotein diagnostics to tailor treatment strategies based on individual patient profiles, further supporting market growth.

Technological advancements in diagnostic testing are also fueling the growth of the immunoprotein diagnostic testing market. Innovations such as high-throughput immunoassay platforms, point-of-care testing devices, and digital health solutions are making diagnostic tests more accessible, accurate, and user-friendly. The development of multiplex testing platforms that can measure multiple biomarkers from a single sample is providing a more comprehensive view of disease states, enabling more precise diagnosis and monitoring. The adoption of digital technologies, such as connectivity features and data-sharing capabilities, is enhancing the integration of immunoprotein diagnostics into broader healthcare ecosystems, supporting telemedicine and remote patient management. As technological innovations continue to improve the performance and accessibility of immunoprotein diagnostic tests, and as the focus on early detection and personalized medicine grows, the global immunoprotein diagnostic testing market is poised for sustained growth, driven by increasing demand from healthcare providers and patients seeking more effective diagnostic solutions.

SCOPE OF STUDY:

The report analyzes the Immunoprotein Diagnostic Testing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Immunoglobulin Diagnostic, Free Light Chain Diagnostic, Pre-Albumin Diagnostic, Haptoglobin Diagnostic, C-Reactive Protein Diagnostic, Complement System Protein Diagnostic, Other Types); Technology (Enzyme-Linked Immunosorbent Assay, Immunoturbidity Assay, Radioimmunoassay, Immunoprotein Electrophoresis, Other Technologies); Application (Infectious Disease Testing, Oncology Testing, Autoimmune Testing, Endocrine Testing, Allergy Testing, Toxicology Testing, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 38 Featured) -

  • Abbott Laboratories
  • Abcam PLC
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation
  • DiaSorin SpA
  • Enzo Biochem, Inc.
  • F. Hoffmann-La Roche AG
  • Ortho Clinical Diagnostics
  • Siemens AG
  • Thermo Fisher Scientific, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
    • Global Economic Update
    • Immunoprotein Diagnostic Testing - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Chronic Diseases Drives Growth in Immunoprotein Diagnostic Testing Market
    • Expansion of Autoimmune Disease and Cancer Diagnostics Spurs Adoption of Immunoprotein Testing
    • Growth in Focus on Early Disease Detection Expands Addressable Market for Immunoprotein Diagnostic Testing
    • Growth in Use of Immunoprotein Testing for Cardiovascular Disease and Inflammatory Disorders Expands Market Opportunities
    • Increasing Focus on Immunoprotein Diagnostic Testing for Infectious Disease Detection Expands Addressable Market
    • Role of Immunoprotein Testing in Supporting Disease Monitoring and Treatment Response Strengthens Market Demand
    • Growth in Use of Immunoprotein Testing for Cancer Prognosis and Therapy Monitoring Expands Market Reach
    • Growth in Use of Immunoprotein Diagnostic Testing for Allergy and Autoimmune Disorders Fuels Market Opportunities
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Immunoprotein Diagnostic Testing Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Immunoprotein Diagnostic Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Immunoprotein Diagnostic Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Immunoprotein Diagnostic Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Immunoglobulin Diagnostic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Immunoglobulin Diagnostic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Immunoglobulin Diagnostic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Free Light Chain Diagnostic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Free Light Chain Diagnostic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Free Light Chain Diagnostic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Pre-Albumin Diagnostic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Pre-Albumin Diagnostic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Pre-Albumin Diagnostic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Haptoglobin Diagnostic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Haptoglobin Diagnostic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Haptoglobin Diagnostic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for C-Reactive Protein Diagnostic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for C-Reactive Protein Diagnostic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for C-Reactive Protein Diagnostic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Complement System Protein Diagnostic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Complement System Protein Diagnostic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Complement System Protein Diagnostic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Enzyme-Linked Immunosorbent Assay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Enzyme-Linked Immunosorbent Assay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Enzyme-Linked Immunosorbent Assay by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Immunoturbidity Assay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Immunoturbidity Assay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Immunoturbidity Assay by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Radioimmunoassay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Radioimmunoassay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Radioimmunoassay by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Immunoprotein Electrophoresis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Immunoprotein Electrophoresis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Immunoprotein Electrophoresis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: World 15-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Infectious Disease Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Infectious Disease Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: World 15-Year Perspective for Infectious Disease Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 44: World Recent Past, Current & Future Analysis for Oncology Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 45: World Historic Review for Oncology Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: World 15-Year Perspective for Oncology Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 47: World Recent Past, Current & Future Analysis for Autoimmune Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 48: World Historic Review for Autoimmune Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: World 15-Year Perspective for Autoimmune Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 50: World Recent Past, Current & Future Analysis for Endocrine Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: World Historic Review for Endocrine Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: World 15-Year Perspective for Endocrine Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 53: World Recent Past, Current & Future Analysis for Allergy Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 54: World Historic Review for Allergy Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: World 15-Year Perspective for Allergy Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 56: World Recent Past, Current & Future Analysis for Toxicology Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 57: World Historic Review for Toxicology Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: World 15-Year Perspective for Toxicology Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 59: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 60: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Immunoprotein Diagnostic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 62: USA Recent Past, Current & Future Analysis for Immunoprotein Diagnostic Testing by Type - Immunoglobulin Diagnostic, Free Light Chain Diagnostic, Pre-Albumin Diagnostic, Haptoglobin Diagnostic, C-Reactive Protein Diagnostic, Complement System Protein Diagnostic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: USA Historic Review for Immunoprotein Diagnostic Testing by Type - Immunoglobulin Diagnostic, Free Light Chain Diagnostic, Pre-Albumin Diagnostic, Haptoglobin Diagnostic, C-Reactive Protein Diagnostic, Complement System Protein Diagnostic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: USA 15-Year Perspective for Immunoprotein Diagnostic Testing by Type - Percentage Breakdown of Value Sales for Immunoglobulin Diagnostic, Free Light Chain Diagnostic, Pre-Albumin Diagnostic, Haptoglobin Diagnostic, C-Reactive Protein Diagnostic, Complement System Protein Diagnostic and Other Types for the Years 2015, 2025 & 2030
    • TABLE 65: USA Recent Past, Current & Future Analysis for Immunoprotein Diagnostic Testing by Technology - Enzyme-Linked Immunosorbent Assay, Immunoturbidity Assay, Radioimmunoassay, Immunoprotein Electrophoresis and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: USA Historic Review for Immunoprotein Diagnostic Testing by Technology - Enzyme-Linked Immunosorbent Assay, Immunoturbidity Assay, Radioimmunoassay, Immunoprotein Electrophoresis and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: USA 15-Year Perspective for Immunoprotein Diagnostic Testing by Technology - Percentage Breakdown of Value Sales for Enzyme-Linked Immunosorbent Assay, Immunoturbidity Assay, Radioimmunoassay, Immunoprotein Electrophoresis and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 68: USA Recent Past, Current & Future Analysis for Immunoprotein Diagnostic Testing by Application - Infectious Disease Testing, Oncology Testing, Autoimmune Testing, Endocrine Testing, Allergy Testing, Toxicology Testing and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: USA Historic Review for Immunoprotein Diagnostic Testing by Application - Infectious Disease Testing, Oncology Testing, Autoimmune Testing, Endocrine Testing, Allergy Testing, Toxicology Testing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: USA 15-Year Perspective for Immunoprotein Diagnostic Testing by Application - Percentage Breakdown of Value Sales for Infectious Disease Testing, Oncology Testing, Autoimmune Testing, Endocrine Testing, Allergy Testing, Toxicology Testing and Other Applications for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 71: Canada Recent Past, Current & Future Analysis for Immunoprotein Diagnostic Testing by Type - Immunoglobulin Diagnostic, Free Light Chain Diagnostic, Pre-Albumin Diagnostic, Haptoglobin Diagnostic, C-Reactive Protein Diagnostic, Complement System Protein Diagnostic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Canada Historic Review for Immunoprotein Diagnostic Testing by Type - Immunoglobulin Diagnostic, Free Light Chain Diagnostic, Pre-Albumin Diagnostic, Haptoglobin Diagnostic, C-Reactive Protein Diagnostic, Complement System Protein Diagnostic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Canada 15-Year Perspective for Immunoprotein Diagnostic Testing by Type - Percentage Breakdown of Value Sales for Immunoglobulin Diagnostic, Free Light Chain Diagnostic, Pre-Albumin Diagnostic, Haptoglobin Diagnostic, C-Reactive Protein Diagnostic, Complement System Protein Diagnostic and Other Types for the Years 2015, 2025 & 2030
    • TABLE 74: Canada Recent Past, Current & Future Analysis for Immunoprotein Diagnostic Testing by Technology - Enzyme-Linked Immunosorbent Assay, Immunoturbidity Assay, Radioimmunoassay, Immunoprotein Electrophoresis and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Canada Historic Review for Immunoprotein Diagnostic Testing by Technology - Enzyme-Linked Immunosorbent Assay, Immunoturbidity Assay, Radioimmunoassay, Immunoprotein Electrophoresis and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Canada 15-Year Perspective for Immunoprotein Diagnostic Testing by Technology - Percentage Breakdown of Value Sales for Enzyme-Linked Immunosorbent Assay, Immunoturbidity Assay, Radioimmunoassay, Immunoprotein Electrophoresis and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 77: Canada Recent Past, Current & Future Analysis for Immunoprotein Diagnostic Testing by Application - Infectious Disease Testing, Oncology Testing, Autoimmune Testing, Endocrine Testing, Allergy Testing, Toxicology Testing and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Canada Historic Review for Immunoprotein Diagnostic Testing by Application - Infectious Disease Testing, Oncology Testing, Autoimmune Testing, Endocrine Testing, Allergy Testing, Toxicology Testing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Canada 15-Year Perspective for Immunoprotein Diagnostic Testing by Application - Percentage Breakdown of Value Sales for Infectious Disease Testing, Oncology Testing, Autoimmune Testing, Endocrine Testing, Allergy Testing, Toxicology Testing and Other Applications for the Years 2015, 2025 & 2030
  • JAPAN
    • Immunoprotein Diagnostic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 80: Japan Recent Past, Current & Future Analysis for Immunoprotein Diagnostic Testing by Type - Immunoglobulin Diagnostic, Free Light Chain Diagnostic, Pre-Albumin Diagnostic, Haptoglobin Diagnostic, C-Reactive Protein Diagnostic, Complement System Protein Diagnostic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Japan Historic Review for Immunoprotein Diagnostic Testing by Type - Immunoglobulin Diagnostic, Free Light Chain Diagnostic, Pre-Albumin Diagnostic, Haptoglobin Diagnostic, C-Reactive Protein Diagnostic, Complement System Protein Diagnostic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Japan 15-Year Perspective for Immunoprotein Diagnostic Testing by Type - Percentage Breakdown of Value Sales for Immunoglobulin Diagnostic, Free Light Chain Diagnostic, Pre-Albumin Diagnostic, Haptoglobin Diagnostic, C-Reactive Protein Diagnostic, Complement System Protein Diagnostic and Other Types for the Years 2015, 2025 & 2030
    • TABLE 83: Japan Recent Past, Current & Future Analysis for Immunoprotein Diagnostic Testing by Technology - Enzyme-Linked Immunosorbent Assay, Immunoturbidity Assay, Radioimmunoassay, Immunoprotein Electrophoresis and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Japan Historic Review for Immunoprotein Diagnostic Testing by Technology - Enzyme-Linked Immunosorbent Assay, Immunoturbidity Assay, Radioimmunoassay, Immunoprotein Electrophoresis and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Japan 15-Year Perspective for Immunoprotein Diagnostic Testing by Technology - Percentage Breakdown of Value Sales for Enzyme-Linked Immunosorbent Assay, Immunoturbidity Assay, Radioimmunoassay, Immunoprotein Electrophoresis and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 86: Japan Recent Past, Current & Future Analysis for Immunoprotein Diagnostic Testing by Application - Infectious Disease Testing, Oncology Testing, Autoimmune Testing, Endocrine Testing, Allergy Testing, Toxicology Testing and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Japan Historic Review for Immunoprotein Diagnostic Testing by Application - Infectious Disease Testing, Oncology Testing, Autoimmune Testing, Endocrine Testing, Allergy Testing, Toxicology Testing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Japan 15-Year Perspective for Immunoprotein Diagnostic Testing by Application - Percentage Breakdown of Value Sales for Infectious Disease Testing, Oncology Testing, Autoimmune Testing, Endocrine Testing, Allergy Testing, Toxicology Testing and Other Applications for the Years 2015, 2025 & 2030
  • CHINA
    • Immunoprotein Diagnostic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 89: China Recent Past, Current & Future Analysis for Immunoprotein Diagnostic Testing by Type - Immunoglobulin Diagnostic, Free Light Chain Diagnostic, Pre-Albumin Diagnostic, Haptoglobin Diagnostic, C-Reactive Protein Diagnostic, Complement System Protein Diagnostic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: China Historic Review for Immunoprotein Diagnostic Testing by Type - Immunoglobulin Diagnostic, Free Light Chain Diagnostic, Pre-Albumin Diagnostic, Haptoglobin Diagnostic, C-Reactive Protein Diagnostic, Complement System Protein Diagnostic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: China 15-Year Perspective for Immunoprotein Diagnostic Testing by Type - Percentage Breakdown of Value Sales for Immunoglobulin Diagnostic, Free Light Chain Diagnostic, Pre-Albumin Diagnostic, Haptoglobin Diagnostic, C-Reactive Protein Diagnostic, Complement System Protein Diagnostic and Other Types for the Years 2015, 2025 & 2030
    • TABLE 92: China Recent Past, Current & Future Analysis for Immunoprotein Diagnostic Testing by Technology - Enzyme-Linked Immunosorbent Assay, Immunoturbidity Assay, Radioimmunoassay, Immunoprotein Electrophoresis and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: China Historic Review for Immunoprotein Diagnostic Testing by Technology - Enzyme-Linked Immunosorbent Assay, Immunoturbidity Assay, Radioimmunoassay, Immunoprotein Electrophoresis and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: China 15-Year Perspective for Immunoprotein Diagnostic Testing by Technology - Percentage Breakdown of Value Sales for Enzyme-Linked Immunosorbent Assay, Immunoturbidity Assay, Radioimmunoassay, Immunoprotein Electrophoresis and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 95: China Recent Past, Current & Future Analysis for Immunoprotein Diagnostic Testing by Application - Infectious Disease Testing, Oncology Testing, Autoimmune Testing, Endocrine Testing, Allergy Testing, Toxicology Testing and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: China Historic Review for Immunoprotein Diagnostic Testing by Application - Infectious Disease Testing, Oncology Testing, Autoimmune Testing, Endocrine Testing, Allergy Testing, Toxicology Testing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: China 15-Year Perspective for Immunoprotein Diagnostic Testing by Application - Percentage Breakdown of Value Sales for Infectious Disease Testing, Oncology Testing, Autoimmune Testing, Endocrine Testing, Allergy Testing, Toxicology Testing and Other Applications for the Years 2015, 2025 & 2030
  • EUROPE
    • Immunoprotein Diagnostic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 98: Europe Recent Past, Current & Future Analysis for Immunoprotein Diagnostic Testing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 99: Europe Historic Review for Immunoprotein Diagnostic Testing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Europe 15-Year Perspective for Immunoprotein Diagnostic Testing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 101: Europe Recent Past, Current & Future Analysis for Immunoprotein Diagnostic Testing by Type - Immunoglobulin Diagnostic, Free Light Chain Diagnostic, Pre-Albumin Diagnostic, Haptoglobin Diagnostic, C-Reactive Protein Diagnostic, Complement System Protein Diagnostic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Europe Historic Review for Immunoprotein Diagnostic Testing by Type - Immunoglobulin Diagnostic, Free Light Chain Diagnostic, Pre-Albumin Diagnostic, Haptoglobin Diagnostic, C-Reactive Protein Diagnostic, Complement System Protein Diagnostic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Europe 15-Year Perspective for Immunoprotein Diagnostic Testing by Type - Percentage Breakdown of Value Sales for Immunoglobulin Diagnostic, Free Light Chain Diagnostic, Pre-Albumin Diagnostic, Haptoglobin Diagnostic, C-Reactive Protein Diagnostic, Complement System Protein Diagnostic and Other Types for the Years 2015, 2025 & 2030
    • TABLE 104: Europe Recent Past, Current & Future Analysis for Immunoprotein Diagnostic Testing by Technology - Enzyme-Linked Immunosorbent Assay, Immunoturbidity Assay, Radioimmunoassay, Immunoprotein Electrophoresis and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Europe Historic Review for Immunoprotein Diagnostic Testing by Technology - Enzyme-Linked Immunosorbent Assay, Immunoturbidity Assay, Radioimmunoassay, Immunoprotein Electrophoresis and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Europe 15-Year Perspective for Immunoprotein Diagnostic Testing by Technology - Percentage Breakdown of Value Sales for Enzyme-Linked Immunosorbent Assay, Immunoturbidity Assay, Radioimmunoassay, Immunoprotein Electrophoresis and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 107: Europe Recent Past, Current & Future Analysis for Immunoprotein Diagnostic Testing by Application - Infectious Disease Testing, Oncology Testing, Autoimmune Testing, Endocrine Testing, Allergy Testing, Toxicology Testing and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Europe Historic Review for Immunoprotein Diagnostic Testing by Application - Infectious Disease Testing, Oncology Testing, Autoimmune Testing, Endocrine Testing, Allergy Testing, Toxicology Testing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Europe 15-Year Perspective for Immunoprotein Diagnostic Testing by Application - Percentage Breakdown of Value Sales for Infectious Disease Testing, Oncology Testing, Autoimmune Testing, Endocrine Testing, Allergy Testing, Toxicology Testing and Other Applications for the Years 2015, 2025 & 2030
  • FRANCE
    • Immunoprotein Diagnostic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 110: France Recent Past, Current & Future Analysis for Immunoprotein Diagnostic Testing by Type - Immunoglobulin Diagnostic, Free Light Chain Diagnostic, Pre-Albumin Diagnostic, Haptoglobin Diagnostic, C-Reactive Protein Diagnostic, Complement System Protein Diagnostic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: France Historic Review for Immunoprotein Diagnostic Testing by Type - Immunoglobulin Diagnostic, Free Light Chain Diagnostic, Pre-Albumin Diagnostic, Haptoglobin Diagnostic, C-Reactive Protein Diagnostic, Complement System Protein Diagnostic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: France 15-Year Perspective for Immunoprotein Diagnostic Testing by Type - Percentage Breakdown of Value Sales for Immunoglobulin Diagnostic, Free Light Chain Diagnostic, Pre-Albumin Diagnostic, Haptoglobin Diagnostic, C-Reactive Protein Diagnostic, Complement System Protein Diagnostic and Other Types for the Years 2015, 2025 & 2030
    • TABLE 113: France Recent Past, Current & Future Analysis for Immunoprotein Diagnostic Testing by Technology - Enzyme-Linked Immunosorbent Assay, Immunoturbidity Assay, Radioimmunoassay, Immunoprotein Electrophoresis and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: France Historic Review for Immunoprotein Diagnostic Testing by Technology - Enzyme-Linked Immunosorbent Assay, Immunoturbidity Assay, Radioimmunoassay, Immunoprotein Electrophoresis and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: France 15-Year Perspective for Immunoprotein Diagnostic Testing by Technology - Percentage Breakdown of Value Sales for Enzyme-Linked Immunosorbent Assay, Immunoturbidity Assay, Radioimmunoassay, Immunoprotein Electrophoresis and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 116: France Recent Past, Current & Future Analysis for Immunoprotein Diagnostic Testing by Application - Infectious Disease Testing, Oncology Testing, Autoimmune Testing, Endocrine Testing, Allergy Testing, Toxicology Testing and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: France Historic Review for Immunoprotein Diagnostic Testing by Application - Infectious Disease Testing, Oncology Testing, Autoimmune Testing, Endocrine Testing, Allergy Testing, Toxicology Testing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: France 15-Year Perspective for Immunoprotein Diagnostic Testing by Application - Percentage Breakdown of Value Sales for Infectious Disease Testing, Oncology Testing, Autoimmune Testing, Endocrine Testing, Allergy Testing, Toxicology Testing and Other Applications for the Years 2015, 2025 & 2030
  • GERMANY
    • Immunoprotein Diagnostic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 119: Germany Recent Past, Current & Future Analysis for Immunoprotein Diagnostic Testing by Type - Immunoglobulin Diagnostic, Free Light Chain Diagnostic, Pre-Albumin Diagnostic, Haptoglobin Diagnostic, C-Reactive Protein Diagnostic, Complement System Protein Diagnostic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Germany Historic Review for Immunoprotein Diagnostic Testing by Type - Immunoglobulin Diagnostic, Free Light Chain Diagnostic, Pre-Albumin Diagnostic, Haptoglobin Diagnostic, C-Reactive Protein Diagnostic, Complement System Protein Diagnostic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Germany 15-Year Perspective for Immunoprotein Diagnostic Testing by Type - Percentage Breakdown of Value Sales for Immunoglobulin Diagnostic, Free Light Chain Diagnostic, Pre-Albumin Diagnostic, Haptoglobin Diagnostic, C-Reactive Protein Diagnostic, Complement System Protein Diagnostic and Other Types for the Years 2015, 2025 & 2030
    • TABLE 122: Germany Recent Past, Current & Future Analysis for Immunoprotein Diagnostic Testing by Technology - Enzyme-Linked Immunosorbent Assay, Immunoturbidity Assay, Radioimmunoassay, Immunoprotein Electrophoresis and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Germany Historic Review for Immunoprotein Diagnostic Testing by Technology - Enzyme-Linked Immunosorbent Assay, Immunoturbidity Assay, Radioimmunoassay, Immunoprotein Electrophoresis and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Germany 15-Year Perspective for Immunoprotein Diagnostic Testing by Technology - Percentage Breakdown of Value Sales for Enzyme-Linked Immunosorbent Assay, Immunoturbidity Assay, Radioimmunoassay, Immunoprotein Electrophoresis and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 125: Germany Recent Past, Current & Future Analysis for Immunoprotein Diagnostic Testing by Application - Infectious Disease Testing, Oncology Testing, Autoimmune Testing, Endocrine Testing, Allergy Testing, Toxicology Testing and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Germany Historic Review for Immunoprotein Diagnostic Testing by Application - Infectious Disease Testing, Oncology Testing, Autoimmune Testing, Endocrine Testing, Allergy Testing, Toxicology Testing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Germany 15-Year Perspective for Immunoprotein Diagnostic Testing by Application - Percentage Breakdown of Value Sales for Infectious Disease Testing, Oncology Testing, Autoimmune Testing, Endocrine Testing, Allergy Testing, Toxicology Testing and Other Applications for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 128: Italy Recent Past, Current & Future Analysis for Immunoprotein Diagnostic Testing by Type - Immunoglobulin Diagnostic, Free Light Chain Diagnostic, Pre-Albumin Diagnostic, Haptoglobin Diagnostic, C-Reactive Protein Diagnostic, Complement System Protein Diagnostic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Italy Historic Review for Immunoprotein Diagnostic Testing by Type - Immunoglobulin Diagnostic, Free Light Chain Diagnostic, Pre-Albumin Diagnostic, Haptoglobin Diagnostic, C-Reactive Protein Diagnostic, Complement System Protein Diagnostic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Italy 15-Year Perspective for Immunoprotein Diagnostic Testing by Type - Percentage Breakdown of Value Sales for Immunoglobulin Diagnostic, Free Light Chain Diagnostic, Pre-Albumin Diagnostic, Haptoglobin Diagnostic, C-Reactive Protein Diagnostic, Complement System Protein Diagnostic and Other Types for the Years 2015, 2025 & 2030
    • TABLE 131: Italy Recent Past, Current & Future Analysis for Immunoprotein Diagnostic Testing by Technology - Enzyme-Linked Immunosorbent Assay, Immunoturbidity Assay, Radioimmunoassay, Immunoprotein Electrophoresis and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Italy Historic Review for Immunoprotein Diagnostic Testing by Technology - Enzyme-Linked Immunosorbent Assay, Immunoturbidity Assay, Radioimmunoassay, Immunoprotein Electrophoresis and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Italy 15-Year Perspective for Immunoprotein Diagnostic Testing by Technology - Percentage Breakdown of Value Sales for Enzyme-Linked Immunosorbent Assay, Immunoturbidity Assay, Radioimmunoassay, Immunoprotein Electrophoresis and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 134: Italy Recent Past, Current & Future Analysis for Immunoprotein Diagnostic Testing by Application - Infectious Disease Testing, Oncology Testing, Autoimmune Testing, Endocrine Testing, Allergy Testing, Toxicology Testing and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Italy Historic Review for Immunoprotein Diagnostic Testing by Application - Infectious Disease Testing, Oncology Testing, Autoimmune Testing, Endocrine Testing, Allergy Testing, Toxicology Testing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Italy 15-Year Perspective for Immunoprotein Diagnostic Testing by Application - Percentage Breakdown of Value Sales for Infectious Disease Testing, Oncology Testing, Autoimmune Testing, Endocrine Testing, Allergy Testing, Toxicology Testing and Other Applications for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Immunoprotein Diagnostic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 137: UK Recent Past, Current & Future Analysis for Immunoprotein Diagnostic Testing by Type - Immunoglobulin Diagnostic, Free Light Chain Diagnostic, Pre-Albumin Diagnostic, Haptoglobin Diagnostic, C-Reactive Protein Diagnostic, Complement System Protein Diagnostic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: UK Historic Review for Immunoprotein Diagnostic Testing by Type - Immunoglobulin Diagnostic, Free Light Chain Diagnostic, Pre-Albumin Diagnostic, Haptoglobin Diagnostic, C-Reactive Protein Diagnostic, Complement System Protein Diagnostic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: UK 15-Year Perspective for Immunoprotein Diagnostic Testing by Type - Percentage Breakdown of Value Sales for Immunoglobulin Diagnostic, Free Light Chain Diagnostic, Pre-Albumin Diagnostic, Haptoglobin Diagnostic, C-Reactive Protein Diagnostic, Complement System Protein Diagnostic and Other Types for the Years 2015, 2025 & 2030
    • TABLE 140: UK Recent Past, Current & Future Analysis for Immunoprotein Diagnostic Testing by Technology - Enzyme-Linked Immunosorbent Assay, Immunoturbidity Assay, Radioimmunoassay, Immunoprotein Electrophoresis and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: UK Historic Review for Immunoprotein Diagnostic Testing by Technology - Enzyme-Linked Immunosorbent Assay, Immunoturbidity Assay, Radioimmunoassay, Immunoprotein Electrophoresis and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: UK 15-Year Perspective for Immunoprotein Diagnostic Testing by Technology - Percentage Breakdown of Value Sales for Enzyme-Linked Immunosorbent Assay, Immunoturbidity Assay, Radioimmunoassay, Immunoprotein Electrophoresis and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 143: UK Recent Past, Current & Future Analysis for Immunoprotein Diagnostic Testing by Application - Infectious Disease Testing, Oncology Testing, Autoimmune Testing, Endocrine Testing, Allergy Testing, Toxicology Testing and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: UK Historic Review for Immunoprotein Diagnostic Testing by Application - Infectious Disease Testing, Oncology Testing, Autoimmune Testing, Endocrine Testing, Allergy Testing, Toxicology Testing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: UK 15-Year Perspective for Immunoprotein Diagnostic Testing by Application - Percentage Breakdown of Value Sales for Infectious Disease Testing, Oncology Testing, Autoimmune Testing, Endocrine Testing, Allergy Testing, Toxicology Testing and Other Applications for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Immunoprotein Diagnostic Testing by Type - Immunoglobulin Diagnostic, Free Light Chain Diagnostic, Pre-Albumin Diagnostic, Haptoglobin Diagnostic, C-Reactive Protein Diagnostic, Complement System Protein Diagnostic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Immunoprotein Diagnostic Testing by Type - Immunoglobulin Diagnostic, Free Light Chain Diagnostic, Pre-Albumin Diagnostic, Haptoglobin Diagnostic, C-Reactive Protein Diagnostic, Complement System Protein Diagnostic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Rest of Europe 15-Year Perspective for Immunoprotein Diagnostic Testing by Type - Percentage Breakdown of Value Sales for Immunoglobulin Diagnostic, Free Light Chain Diagnostic, Pre-Albumin Diagnostic, Haptoglobin Diagnostic, C-Reactive Protein Diagnostic, Complement System Protein Diagnostic and Other Types for the Years 2015, 2025 & 2030
    • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Immunoprotein Diagnostic Testing by Technology - Enzyme-Linked Immunosorbent Assay, Immunoturbidity Assay, Radioimmunoassay, Immunoprotein Electrophoresis and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Rest of Europe Historic Review for Immunoprotein Diagnostic Testing by Technology - Enzyme-Linked Immunosorbent Assay, Immunoturbidity Assay, Radioimmunoassay, Immunoprotein Electrophoresis and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Rest of Europe 15-Year Perspective for Immunoprotein Diagnostic Testing by Technology - Percentage Breakdown of Value Sales for Enzyme-Linked Immunosorbent Assay, Immunoturbidity Assay, Radioimmunoassay, Immunoprotein Electrophoresis and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 152: Rest of Europe Recent Past, Current & Future Analysis for Immunoprotein Diagnostic Testing by Application - Infectious Disease Testing, Oncology Testing, Autoimmune Testing, Endocrine Testing, Allergy Testing, Toxicology Testing and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Rest of Europe Historic Review for Immunoprotein Diagnostic Testing by Application - Infectious Disease Testing, Oncology Testing, Autoimmune Testing, Endocrine Testing, Allergy Testing, Toxicology Testing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Rest of Europe 15-Year Perspective for Immunoprotein Diagnostic Testing by Application - Percentage Breakdown of Value Sales for Infectious Disease Testing, Oncology Testing, Autoimmune Testing, Endocrine Testing, Allergy Testing, Toxicology Testing and Other Applications for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Immunoprotein Diagnostic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Immunoprotein Diagnostic Testing by Type - Immunoglobulin Diagnostic, Free Light Chain Diagnostic, Pre-Albumin Diagnostic, Haptoglobin Diagnostic, C-Reactive Protein Diagnostic, Complement System Protein Diagnostic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Immunoprotein Diagnostic Testing by Type - Immunoglobulin Diagnostic, Free Light Chain Diagnostic, Pre-Albumin Diagnostic, Haptoglobin Diagnostic, C-Reactive Protein Diagnostic, Complement System Protein Diagnostic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 15-Year Perspective for Immunoprotein Diagnostic Testing by Type - Percentage Breakdown of Value Sales for Immunoglobulin Diagnostic, Free Light Chain Diagnostic, Pre-Albumin Diagnostic, Haptoglobin Diagnostic, C-Reactive Protein Diagnostic, Complement System Protein Diagnostic and Other Types for the Years 2015, 2025 & 2030
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Immunoprotein Diagnostic Testing by Technology - Enzyme-Linked Immunosorbent Assay, Immunoturbidity Assay, Radioimmunoassay, Immunoprotein Electrophoresis and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Immunoprotein Diagnostic Testing by Technology - Enzyme-Linked Immunosorbent Assay, Immunoturbidity Assay, Radioimmunoassay, Immunoprotein Electrophoresis and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Asia-Pacific 15-Year Perspective for Immunoprotein Diagnostic Testing by Technology - Percentage Breakdown of Value Sales for Enzyme-Linked Immunosorbent Assay, Immunoturbidity Assay, Radioimmunoassay, Immunoprotein Electrophoresis and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Immunoprotein Diagnostic Testing by Application - Infectious Disease Testing, Oncology Testing, Autoimmune Testing, Endocrine Testing, Allergy Testing, Toxicology Testing and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Asia-Pacific Historic Review for Immunoprotein Diagnostic Testing by Application - Infectious Disease Testing, Oncology Testing, Autoimmune Testing, Endocrine Testing, Allergy Testing, Toxicology Testing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Asia-Pacific 15-Year Perspective for Immunoprotein Diagnostic Testing by Application - Percentage Breakdown of Value Sales for Infectious Disease Testing, Oncology Testing, Autoimmune Testing, Endocrine Testing, Allergy Testing, Toxicology Testing and Other Applications for the Years 2015, 2025 & 2030
  • REST OF WORLD
    • TABLE 164: Rest of World Recent Past, Current & Future Analysis for Immunoprotein Diagnostic Testing by Type - Immunoglobulin Diagnostic, Free Light Chain Diagnostic, Pre-Albumin Diagnostic, Haptoglobin Diagnostic, C-Reactive Protein Diagnostic, Complement System Protein Diagnostic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of World Historic Review for Immunoprotein Diagnostic Testing by Type - Immunoglobulin Diagnostic, Free Light Chain Diagnostic, Pre-Albumin Diagnostic, Haptoglobin Diagnostic, C-Reactive Protein Diagnostic, Complement System Protein Diagnostic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Rest of World 15-Year Perspective for Immunoprotein Diagnostic Testing by Type - Percentage Breakdown of Value Sales for Immunoglobulin Diagnostic, Free Light Chain Diagnostic, Pre-Albumin Diagnostic, Haptoglobin Diagnostic, C-Reactive Protein Diagnostic, Complement System Protein Diagnostic and Other Types for the Years 2015, 2025 & 2030
    • TABLE 167: Rest of World Recent Past, Current & Future Analysis for Immunoprotein Diagnostic Testing by Technology - Enzyme-Linked Immunosorbent Assay, Immunoturbidity Assay, Radioimmunoassay, Immunoprotein Electrophoresis and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of World Historic Review for Immunoprotein Diagnostic Testing by Technology - Enzyme-Linked Immunosorbent Assay, Immunoturbidity Assay, Radioimmunoassay, Immunoprotein Electrophoresis and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Rest of World 15-Year Perspective for Immunoprotein Diagnostic Testing by Technology - Percentage Breakdown of Value Sales for Enzyme-Linked Immunosorbent Assay, Immunoturbidity Assay, Radioimmunoassay, Immunoprotein Electrophoresis and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 170: Rest of World Recent Past, Current & Future Analysis for Immunoprotein Diagnostic Testing by Application - Infectious Disease Testing, Oncology Testing, Autoimmune Testing, Endocrine Testing, Allergy Testing, Toxicology Testing and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Rest of World Historic Review for Immunoprotein Diagnostic Testing by Application - Infectious Disease Testing, Oncology Testing, Autoimmune Testing, Endocrine Testing, Allergy Testing, Toxicology Testing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Rest of World 15-Year Perspective for Immunoprotein Diagnostic Testing by Application - Percentage Breakdown of Value Sales for Infectious Disease Testing, Oncology Testing, Autoimmune Testing, Endocrine Testing, Allergy Testing, Toxicology Testing and Other Applications for the Years 2015, 2025 & 2030

IV. COMPETITION